Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.

Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition.
Clin Cancer Res. 2018 Jul 24;:
Authors: Johnson DB, Dahlman KB
Abstract
Mutations in BRAF outside of the 600 codon (BRAF non-V600) occur across cancer types, including in 3-5% of melanomas. The optimal treatment strategies are not clear, but could include MEK inhibitors based on pre-clinical studies. Combining BRAF and MEK inhibitors in this population may provide additional benefit.
PMID: 30042206 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - July 24, 2018 Category: Cancer & Oncology Authors: Johnson DB, Dahlman KB Tags: Clin Cancer Res Source Type: research